2 completed, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow RP7214: new trials by email Literature Review of RP7214 trials Research Report on RP7214
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia RP7214 - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Withdrawn | Rhizen Pharmaceuticals SA | 2023-01-01 | 2022-10-31 | |
| Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. RP7214 + Standard of care (SOC), Placebo + Standard of care (SOC) - SARS-CoV-2 Infection | Phase 2 | Completed | Rhizen Pharmaceuticals SA | 163 | 2021-09-20 | 2022-04-21 |
| A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects RP7214, Placebo - Healthy Volunteers | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 42 | 2020-12-29 | 2021-08-18 |
COVID-19 (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1)
India (1) · United States (1)